For clinicians · latest clinical updates

What changed. What the evidence shows. What it does not.

Dated, source-linked notes on developments relevant to women’s cardiovascular health. Technical detail lives here so the public education pages can stay clear and personally useful.

September 4, 2026 · Lp(a) · Outcomes trial

Lp(a)HORIZON: pelacarsen did not meet its primary endpoint

What changed?

Novartis reported that pelacarsen lowered Lp(a) but did not significantly reduce the primary composite cardiovascular endpoint in the overall trial population.

What does the evidence actually show?

Lowering a biomarker is not, by itself, proof that a treatment improves clinical outcomes. Full peer-reviewed results and subgroup analyses are needed to understand the finding.

What does it not show?

This does not erase the observational and genetic evidence that elevated Lp(a) can mark higher cardiovascular risk. It also does not establish outcome benefit for pelacarsen.

Does this change practice today?

Continue to use Lp(a) as a risk-enhancing factor in overall prevention conversations. Do not present pelacarsen as an established outcome-improving therapy.

What should we watch next?

Peer-reviewed trial publication, prespecified subgroup results, safety data, and outcomes from other Lp(a)-lowering programs.

Primary source: Novartis topline results (opens in a new tab)

March 13, 2026 · Prevention · Dyslipidemia

The 2026 ACC/AHA dyslipidemia guideline expands risk refinement

What changed?

The updated guideline emphasizes earlier prevention, recommends Lp(a) measurement at least once in adulthood, supports selective ApoB use, and gives coronary calcium a role in selected uncertain decisions.

What does the evidence actually show?

Risk assessment can extend beyond LDL-C alone when family history, metabolic context, inherited risk, or uncertainty changes the question.

What does it not show?

It does not make every advanced test appropriate for every patient, and no single biomarker or scan replaces the clinical picture.

Does this change practice today?

Review lifetime exposure and risk enhancers, then use additional testing when the result is reasonably likely to change a decision.

What should we watch next?

Implementation details, patient access, and how newer evidence changes treatment thresholds over time.

Primary source: ACC/AHA guideline (opens in a new tab)

February 12, 2026 · Menopause · Regulation

FDA approved labeling changes for initial menopausal hormone therapy products

What changed?

FDA approved revised labeling for an initial six products, including removal of certain cardiovascular disease, breast cancer, and probable dementia statements from boxed warnings. Other important risk information remains.

What does the evidence actually show?

Label language and the evidence conversation have changed. Treatment decisions still depend on the product, route, timing, symptoms, contraindications, and individual history.

What does it not show?

The action does not make hormone therapy risk-free, appropriate for everyone, or a treatment to prevent cardiovascular disease.

Does this change practice today?

Use shared decision-making grounded in current labeling and the woman’s goals and history; avoid turning a regulatory headline into a universal recommendation.

What should we watch next?

Additional product-label revisions and specialty-society implementation guidance.

Primary source: U.S. Food and Drug Administration (opens in a new tab)

April 12, 2024 · Pregnancy history · Prevention

Postpartum care is a bridge to long-term cardiovascular prevention

What changed?

The AHA scientific statement consolidated practical approaches to cardiovascular risk reduction after adverse pregnancy outcomes.

What does the evidence actually show?

Hypertensive disorders of pregnancy, gestational diabetes, preterm delivery, placental abruption, and fetal growth restriction are associated with later cardiovascular risk and warrant durable history-taking and follow-up.

What does it not show?

An association is not destiny. The evidence does not mean every pregnancy experience independently predicts maternal cardiovascular disease or mandates the same testing pathway.

Does this change practice today?

Ask, document, and carry recognized adverse pregnancy outcomes forward alongside current blood pressure, lipids, glucose, symptoms, family history, and care context.

What should we watch next?

Implementation research on record portability, equitable follow-up, and effective transitions from obstetric to primary and cardiovascular care.

Primary source: American Heart Association scientific statement (opens in a new tab)

March 29, 2025 · INOCA · Trial results

WARRIOR: intensive medical therapy did not significantly reduce the primary outcome

What changed?

In women with suspected ischemia and no obstructive coronary artery disease, the pragmatic WARRIOR trial did not show a statistically significant reduction in its primary composite outcome with the intensive strategy tested.

What does the evidence actually show?

The result underscores the difficulty of translating a heterogeneous INOCA population into one uniform treatment strategy and the need to define mechanism and phenotype carefully.

What does it not show?

It does not show that persistent symptoms are unreal, that INOCA is unimportant, or that individualized risk-factor care and symptom evaluation should stop.

Does this change practice today?

Avoid overclaiming one universal regimen. Continue mechanism-aware evaluation, symptom care, and prevention based on the full clinical context.

What should we watch next?

Complete publication, phenotype-specific analyses, adherence and crossover effects, and trials that match treatment to coronary mechanism.

Primary source: American College of Cardiology trial summary (opens in a new tab)

See something that needs correction?

Focused review is welcome.

Identify the exact statement and the best primary source. Review is not presented as endorsement.

Send a focused correction